Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2024-02-22 00:00:00 ET · period of report 2024-02-20 · accession 0001415889-24-004903 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-22 | 2024-02-20 | JBIO | Gillies Hunter | Chief MEDICAL Off | S - Sale+OE | $20.23 | -3,489 | 3,251 | -52% | -$70.6K |
| D | 2024-02-22 | 2024-02-20 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $1.74 | +3,489 | 6,740 | +107% | +$6,071 |
| DM | 2024-02-22 | 2024-02-20 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $0.00 | -3,489 | 8,036 | -30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-20 | S | D | 2,591 | $20.11 | 4,149 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.53 to $20.515, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2024-02-20 | M | A | 3,489 | $1.74 | 6,740 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-20 | S | D | 898 | $20.58 | 3,251 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.55 to $20.67, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-02-20 | M | D | 2,502 | $0.00 | 3,525 | D | $1.74 · — to 2030-09-03 | 2,502 Common Stock | (F4) A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-02-20 | M | D | 987 | $0.00 | 8,036 | D | $1.74 · — to 2030-09-03 | 987 Common Stock | (F5) A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |